There are currently 1248 clinical trials in Nashville, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University and Sarah Cannon Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Recruiting
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily [QD] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations. A target of approximately 375 patients will be randomized in a 1:1:1 ratio to treatmen... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: ArriVent Investigative Site, Nashville, Tennessee
Conditions: Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
Recruiting
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE).
Gender:
All
Ages:
30 years and above
Trial Updated:
06/14/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
Recruiting
This phase 3 trial compares the addition of nivolumab to chemotherapy (carboplatin and paclitaxel) versus usual treatment (chemotherapy alone) for the treatment of anal cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Anal Canal Cloacogenic Carcinoma, Metastatic Anal Squamous Cell Carcinoma, Recurrent Anal Squamous Cell Carcinoma, Stage III Anal Cancer AJCC v8, Stage IV Anal Cancer AJCC v8, Unresectable Anal Squamous Cell Carcinoma, Anal Basaloid Squamous Cell Carcinoma
Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP)
Recruiting
The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead. The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD Lead and is designed to confirm the safety and defibrillation efficacy of the Next Generation ICD Lead when placed in the LBBAP location in ICD and LOT-CRT patient population.
Gender:
All
Ages:
12 years and above
Trial Updated:
06/14/2024
Locations: LEADR: Vanderbilt University medical Center, Nashville, Tennessee
Conditions: Tachyarrhythmia
Nectero EAST System Clinical Study
Recruiting
The purpose of this randomized clinical trial is to treat patients with small to mid-sized abdominal aortic aneurysms (AAA), maximum diameter of 3.5 cm to 5.0 cm, using a locally delivered, single-dose endovascular treatment. The main question the study aims to answer is to demonstrate efficacy of the product for stabilization of these small to mid-sized AAA.The study will compare the treatment group to the typical standard of care for these patients, surveillance. All subjects will be followed... Read More
Gender:
All
Ages:
Between 21 years and 85 years
Trial Updated:
06/14/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Abdominal Aortic Aneurysm
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Recruiting
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either dr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Clinical Research Associates, Nashville, Tennessee +1 locations
Conditions: Type 2 Diabetes
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Recruiting
This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes. As of June 4, 2024, this study is no longer accepting any newly screened participants.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: SCRI Oncology Partners, Nashville, Tennessee
Conditions: Breast Cancer
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Recruiting
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to <18 years of age with PAH World Health Organization (WHO) Group 1 on standard of care (SoC). There is no formal hypothesis.
Gender:
All
Ages:
Between 1 year and 17 years
Trial Updated:
06/14/2024
Locations: Monroe Carell Jr. Children's Hospital ( Site 1601), Nashville, Tennessee
Conditions: Pulmonary Arterial Hypertension
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
Recruiting
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/14/2024
Locations: Vanderbilt Hepatology and Liver Transplant, Nashville, Tennessee
Conditions: Primary Biliary Cirrhosis
Wearable Technology to Evaluate Hyperglycemia and HRV in DMD - Longitudinal Aim
Recruiting
Duchenne Muscular Dystrophy (DMD) is an X-linked disorder that causes muscle wasting, cardiopulmonary failure, and premature death. Heart failure is a leading cause of death in DMD, but substantial knowledge gaps exist regarding predisposing risk factors. In the general population, hyperglycemia, insulin resistance, and decreased heart rate variability (HRV; reflecting autonomic dysfunction) are associated with cardiomyopathy (CM). It is unclear whether these factors are associated with DMD-CM.... Read More
Gender:
Male
Ages:
10 years and above
Trial Updated:
06/14/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Duchenne Muscular Dystrophy
Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Local Institution - 0043, Nashville, Tennessee
Conditions: Multiple Myeloma
A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence
Recruiting
The masseter muscle is one of the muscles in the lower face used for chewing. The prominence of the masseter muscle can appear as a widened lower face which some individuals deem as aesthetically undesirable and can be treated by selectively weakening the masseter muscles with small quantities of botulinum toxin. The purpose of this study is to assess how safe and effective injection of onabotulinumtoxinA (BOTOX) is in adult participants with Masseter Muscle Prominence (MMP). BOTOX is being inv... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Tennessee Clinical Research Center /ID# 248486, Nashville, Tennessee
Conditions: Masseter Muscle Prominence